Although recent clinical studies have suggested that long-acting calcium channel blockers (CCBs) have beneficial effects on heart failure, the precise mechanism is unknown. In this study, Dahl salt-sensitive rats fed a high salt diet were treated with the long-acting CCB amlodipine, the low-molecular-weight membrane permeable superoxide dismutase mimetic 4-hydroxy-2,2,6,6-tetramethyl piperidinoxyl (Tempol), or saline from 11 weeks after birth. The cardiac geometry and function, and gene expression profiles were determined at 17 weeks. Dahl salt-sensitive rats fed a high salt diet followed by saline as a non-treatment control (HS group) showed a marked increase in blood pressure and developed concentric hypertrophy at 11 weeks, fol- 
Introduction
Hemodynamic overload, which can take the form of pressure or volume overload, causes left ventricular (LV) hypertrophy as an adaptive mechanism. However, sustained cardiac hypertrophy induces a reduction of contractile ability and/or a decrease in the number of viable myocytes, resulting in congestive heart failure (CHF) (1) (2) (3) (4) . It is very important to elucidate the molecular mechanism of the progression from cardiac hypertrophy to heart failure (5).
Calcium channel blockers (CCBs) are widely used to treat patients with hypertension (6) , but treatment with short-acting CCBs has been reported to increase the risk of cardiovascular death, at least partly due to activation of the sympathetic nervous system (7) (8) (9) . However, CCBs with an intrinsically long duration of activity have been shown to significantly reduce vascular resistance properties without significant effects on myocardial contractility (10) . In the ACTION (A Coronary disease Trial Investigating Outcome with Nifedipine GITS [gastro-intestinal therapeutic system]) trial, the addition of long-acting nifedipine to conventional treatment of stable angina patients reduced the development of heart failure by 29% (11, 12) .
Amlodipine, a third generation dihydropyridine CCB, has much higher affinity for lipid constituents of the cellular membrane than do other CCBs (13) . There are increasing basic and clinical data indicating that amlodipine and other CCBs, in addition to having hemodynamic properties, exert non-calcium channel-related pleiotropic actions, such as the release of nitric oxide (14) , inhibition of adhesion molecules (15) and inhibition of matrix metalloproteinase-1 (16) . Moreover, amlodipine inhibits cytokine-induced endothelial cell toxicity and has a potent membrane antioxidant activity independent of its calcium channel modulation (17) . To determine whether amlodipine prevents the progression from hypertrophy to heart failure, we used a Dahl rat hypertensive heart failure model (18) (19) (20) (21) (22) , and to gain insight into the underlying mechanisms of the effects of amlodipine, we performed DNA chip analysis (23, 24) .
Methods Animals
Five-week-old male Dahl salt-sensitive rats (DS) were obtained from SLC (Shizuoka, Japan). All rats were housed in climate-controlled metabolic cages with a 12:12-h light-dark cycle. Twenty-four rats were fed a diet containing 0.3% NaCl until the age of 6 weeks, then fed a diet containing 8% NaCl (MF; Oriental Yeast, Tokyo, Japan) from 6 weeks of age until the end of the experiment. Seven of these 24 rats were then given amlodipine (10 mg/kg/day) by gavage once a day from 11 weeks to 17 weeks (AMLO group), 7 were given the lowmolecular-weight membrane permeable superoxide dismutase (SOD) mimetic, 4-hydroxy-2,2,6,6-tetramethyl piperidinoxyl (Tempol; 10 mg/kg/day), by gavage once a day from 11 weeks to 17 weeks (TEMP group) and 10 rats were treated with saline as a non-treatment control (HS group). In addition, 10 rats were fed a diet containing 0.3% NaCl throughout this experiment as a normal blood pressure control (LS group). The blood pressure (BP) and body weight (BW) of all animals were measured every week. The peak systolic pressure was recorded by a photoelectric pulse device (Softron BP-98A; Softron Co., Tokyo, Japan) placed on the tail of unanesthetized rats as described previously (25) . At 17 weeks of age, all DS rats with or without CHF were sacrificed, before their natural death, when signs of CHF such as rapid and labored respiration and LV diffuse hypokinesis on echocardiography were observed.
Throughout the studies, all animals were treated humanely in accordance with the guidelines on animal experimentation of our institute and the Position of the American Heart Association on Research Animal Use. All protocols were approved 10, 10, 7, 7, respectively 
Echocardiography
The LV dimension, contraction, LV wall thickness, and LV fractional shortening (FS) were determined by echocardiography after anesthesia with an intramuscular injection of pentobarbital sodium (15 mg/kg BW). Transthoracic echocardiography was performed at the ages of 6, 11, and 17 weeks in all rats using an HP Sonos 5500 (Hewlett-Packard Co., Andover, USA) with a 10-MHz imaging linear scan probe transducer as described previously (25, 26) .
Histological Analysis
The heart was weighed, then fixed by perfusion with 3.8% formaldehyde, embedded in paraffin, sectioned into 4 μm slices, and stained with hematoxylin-eosin (H-E) or van Gieson stain (25) . To determine the degree of collagen fiber accumulation, we selected 10 fields at random and calculated the ratio of the fibrotic area by van Gieson staining to the total myocardial area by using NIH IMAGE software (NIH Research Service Branch, Bethesda, USA) (25) . Apoptosis was detected by in situ terminal deoxynucleotidyl transfermediated end labeling of fragmented nuclei (TUNEL assay) using an in situ apoptosis detection kit (CardioTACS ™ ; TRE-VIGEN Inc., Gaithersburg, USA) according to the supplier's instructions. The oxidation of the myocardium was determined by immunostaining using anti-4-hydroxy-2-nonenal antibody (anti-4-HNE; ALEXIS Biochemicals, USA) reacted with avidin-conjugated peroxidase (VECTASTAIN ABC kit, VECTOR, Burlingame, USA), and visualized with 3,3′-diaminobenzidine (Peroxidase substrate kit DAB, VECTOR). For semiquantification, the area and the intensity of 4-HNE staining were scored as reported previously (27) . A part of the LV was frozen at −80°C for mRNA analysis.
RNA Preparation and DNA Microarray Analysis
Total RNA was isolated from rat heart ventricles using the lithium/urea method and separated on a 1.0% agarose/formaldehyde gel. cDNA of brain natriuretic peptide (BNP) was labeled by a random priming method with [α-32 P]dCTP and hybridized to membranes as described previously (25) . An RNase protection assay (using 20 μg of total RNA) was performed using a rat cytokine Multi-Probe Template Set (BD Pharmingen Bioscience, San Jose, USA) according to the RNA was purified from the total RNA with a QuickPrep mRNA purification kit (Pharmacia Biotech, Piscataway, USA). The experimental procedures for the gene chip analysis were performed according to the Affymetrix GeneChip Expression Analysis Technical Manual (Affymetrix, Santa Clara, USA) (28) (29) (30) . The Affymetrix GeneChip U34A set was derived from selected genes and ESTs from the 18 November 1998 release of Genbank. Each 8800 gene is represented on the arrays by perfectly matched 25-mer (PM) oligonucleotides and mismatched (MM) 25-mer control probes that are identical except for one base. The expression levels were calculated by background-subtracting the hybridization signal of MM from its PM partner and averaging the difference for the probe pair set for individual genes. The RNA levels of each gene were scanned and scored for which the computer algorithm (Affymetrix) returned a "present" call. All calculations were performed by Affymetrix software (31) . The data were analyzed by the program FileMaker Pro 4.0 for Macintosh. Among the 8,800 clones included in the gene chip analysis, we selected those genes having an intensity of >100. Among these genes, we picked out ratio values > 1.7 or < −1.7 as indicating genes with changed expression.
Statistical Analysis
All data are expressed as the mean±SEM of 3-4 independent experiments. Mean differences among the 4 groups were tested by one-way ANOVA followed by Scheffe's modified F-test for multiple comparisons. Comparisons of follow-up body weight, blood pressure, pulse rate and echocardiographic data were tested using repeated measure ANOVA followed by Scheffe's modified F-test. Values of p< 0.05 were considered statistically significant.
Results

Development of Cardiac Hypertrophy and Heart Failure in Dahl Salt-Sensitive Rats
A loss of body weight was observed in HS rats, but the treatment with amlodipine significantly attenuated it (Fig. 1A) . The initial systolic BP (SBP) at 6 weeks of age was 108.5±11.4 mmHg (mean±SEM, n= 34). SBP was gradually increased, reached a level of over 200 mmHg by 11 weeks, and remained over 200 mmHg thereafter in HS rats. The SBP was not decreased in AMLO or TEMP rats and there was no significant difference in SBP among HS, AMLO and TEMP rats (Fig. 1B) . At the age of 14-16 weeks, all HS rats lost BW and displayed rapid and labored respiration characteristic of CHF, and by 17 weeks, 5 of 10 rats had died. On the other hand, all LS rats were alive without any symptoms and 6 of 7 10, 5, 6, 4, respectively 
Fig. 3. The heart-weight-to-body-weight ratio of DS rats at 17 weeks. A: H-E staining of the heart of LS, HS, AMLO and TEMP rats at 17 weeks (n= 10, 5, 6, 4, respectively). The bar indicates 5 mm. B: The heart-weight-to-body-weight ratio of LS, HS, AMLO and TEMP rats at 17 weeks (n=
Echocardiography
We assessed cardiac geometry and function by echocardiography. In accordance with the increase of SBP, LV wall thickness was increased in HS rats at 17 weeks compared to LS rats ( Fig. 2A) . The diastolic interventricular septum wall thickness (IVSTd) was significantly thinner in AMLO and TEMP rats than in HS rats ( Fig. 2A) . The calculated LV mass was increased in HS rats, and treatment with either amlodipine or Tempol reduced it (Fig. 2B ). In parallel with the progression of the symptoms of heart failure, LV was dilated (Fig. 2C ) and the contraction was impaired (Fig. 2D ) in HS rats compared with LS rats. The treatment with either amlodipine or Tempol significantly attenuated the development of LV hypertrophy and dilatation, and improved contraction ( Fig. 2A-D) .
Histopathology of the Heart
HS rats developed remarkable cardiac hypertrophy compared with LS rats (the weights of the hearts of 17-week-old animals were as follows: LS, (Fig. 3) . Marked cardiomyocyte hypertrophy and interstitial fibrosis were observed in the LV tissue of 17-week-old HS rats compared to LS rats (Fig. 4A ). Quantitative analysis of myocardial fibrosis using van Gieson staining of the heart tissue revealed that the treatment with either amlodipine or Tempol significantly reduced the fibrotic area compared to that in HS rats (LS, (Fig. 4B ). Apoptosis has been reported to be involved in the pathophysiology of the development of heart failure in DS rats (32) . The number of apoptotic cells was increased in HS rats compared to LS rats, but the treatment with either amlodipine or Tempol significantly reduced the number of apoptotic cells detected by the TUNEL method (Fig. 4C) . Since the staining score of 4-HNE (a by-product of lipid peroxidation and an indicator of oxidative stress) of the myocardium was increased in HS hearts compared to LS hearts, it was improved in AMLO and TEMP hearts (Fig. 4D, E) .
Effects of Amlodipine Treatment on Gene Expression
The mRNA levels of brain natriuretic peptide (BNP) and interleukin (IL)-1β were significantly higher in HS rats compared to LS rats, as reported previously (33) , indicating that this model of hypertensive heart failure was reliable. The treatment with either amlodipine or Tempol significantly reduced the expression levels of BNP (Fig. 5A ) and IL-1β (Fig. 5B) genes. Other myocardial gene expression profiling results were obtained from the gene chip analysis of RNA samples from the hearts of each group. Upregulations of the natriuretic peptide factor precursor A (ANF), BNP, c-fos, β-myosin heavy chain (β-MHC) and Egr-1 genes (data not shown), all of which are known to be upregulated in CHF, were detected by the gene chip, suggesting the reliability of the RNA expression analysis. Since both amlodipine and Tempol significantly inhibited the transition of LV hypertrophy to heart failure, we compared the gene expression profile of each heart treated with either amlodipine or Tempol using a gene chip. Amlodipine treatment changed the expression of 195 genes, and some of these genes may be involved in the beneficial effects of amlodipine on heart failure. Among these 195 genes, 110 genes were increased in HS rats and decreased in AMLO rats. And of these 110 genes, 54 genes were also decreased in TEMP rats (Table 1) . Eighty-five genes were decreased in HS rats and increased in AMLO rats. Of these 85 genes, 38 genes were also increased in TEMP rats ( Table 2 ).
The genes that changed in a similar fashion in both AMLO and TEMP rats may have been involved in the antioxidative mechanisms of amlodipine on hypertensive heart failure. Fibrosis-related genes (arachidonate 12-lipoxygenase, trans- HS/LS, the fold change the gene expression of HS to LS rat; AMLO/HS, the fold change the gene expression of AMLO to HS rat; TEMP/HS, the fold change the gene expression of TEMP to HS.
forming growth factor-β and fibronectin) and proinflammatory/proapoptotic genes (pancreatitis-associated protein, lysyl oxidase, sialoprotein, prostaglandin F2α receptor, galectin-5, enolase 1) were included among the 54 genes that were increased in HS rats but decreased in AMLO and TEMP rat. Several Ca-handling protein genes, such as voltage-dependent protein, T type protein, α1G subunit protein, S100 Cabinding protein A4, cerebellar Ca-binding protein, and spot 35 protein genes were also included. By contrast, several genes, i.e., aquaporin 9, CD74, vitronectin, mitogen-activated protein kinase kinase (MAPKK) and A-raf, were upregulated by the treatment with either amlodipine or Tempol.
Discussion
In the present study, we demonstrated the beneficial effects of the long-term CCB amlodipine on hypertensive heart failure. Treatment with amlodipine significantly reduced the heart weight, LV wall thickness and LV diameter, and improved LV systolic function. Increases in expression levels of the BNP and IL-1β gene were inhibited by the treatment with amlodipine. Moreover, we investigated the changes in the expression levels of a large number of genes in the hearts of LS, HS, AMLO and TEMP rats at the heart failure stage.
In this study, we used Tempol as an antioxidative drug. Tempol is a low-molecular-weight super oxide dismutase mimetic that is both metal-independent and cell membrane permeable. Several investigators have suggested that Tempol reduces O2-induced damage during inflammation, radiation, and ischemic/reperfusion injury. Although Tempol improved the cardiac function and hypertrophy in our study, the mortality and the BW loss were not improved. This chemical compound may cause some systemic adverse effects. Since the inhibitory effect of Tempol on the hypertrophied heart is controversial, the mechanisms of the induction of the hypertrophy such as hypoxia (34) , isoproterenol (35) or aldosterone (36) may be related to the difference.
Many factors, such as the renin-angiotensin system (37), calcineurin (26, 38) , the endothelin-system (33, 39) , and IL-1β (33) , have been reported to be involved in the transition from compensated cardiac hypertrophy to decompensated heart failure in DS rats. They also include abnormalities in calcium handling, apoptosis of cardiac myocytes, increases in cytokine expression and extracellular matrix, and activation of neurohumoral factors. The DS rat develops systemic hypertension, depending on the amount of sodium supplied in the diet, and cardiac hypertrophy with interstitial fibrosis. Prolonged hypertension induces reduced myocardial contraction and relaxation velocities (19, 20) , indicating that this model fully recapitulates the phenotype of human LV hypertrophy and hypertensive heart failure.
Treatment with short-acting CCBs may worsen heart failure and increase the risk of death in patients with advanced LV dysfunction. Amlodipine can regulate membrane fluidity and cholesterol deposition, stimulate NO production to recruit its biologic actions, and regulate matrix deposition. Recognition of the ancillary actions of amlodipine is important for understanding the agent's mechanisms of action and the pathologic mechanisms underlying cardiovascular disease. The antioxidant properties of amlodipine are attributed to its chemical structure and direct physicochemical interactions with the membrane lipid bilayer, as evidenced by changes in membrane thermodynamic properties (40) . Oxidative stress is widely known to play important roles in the pathophysiology of hypertensive heart failure. In the present study, treatment with amlodipine improved the degree of cardiac hypertrophy, dilatation, contraction and mortality. The improvement of cardiac fibrosis and a decrease in apoptosis may be involved in the mechanism of the beneficial effects of amlodipine.
Although it is difficult to analyze the pathophysiological mechanism by which amlodipine inhibits the progression of heart failure, our finding that the drug altered the expression levels of various genes may provide a clue.
An antioxidative mechanism may be involved in the beneficial effects of amlodipine in heart failure. Amlodipine has been reported to inhibit oxidative stress in the hypertensive hypertrophied heart (41) . By the treatment with amlodipine, 195 genes were changed and these genes may be involved in the beneficial effects of amlodipine on heart failure. Among these 195 genes, 110 genes were increased in HS rats and decreased in AMLO rats. In 110 genes, 54 genes were also decreased in TEMP rats. These genes that were changed in a similar fashion in AMLO and TEMP rats may be involved in the antioxidative mechanisms of amlodipine on hypertensive heart failure. Many of these genes have been classified as cell signaling-related genes. Since fibrosis-related genes such as arachidonate 12-lipoxygenase (42), transforming growth factor-β and fibronectin are known to be involved in the pathophysiology of cardiac fibrosis, they were changed similarly by the treatment with either amlodipine or Tempol. Proinflammatory and/or proapoptotic genes such as pancreatitisassociated protein, lysyl oxidase, sialoprotein, prostaglandin F2α receptor, galectin-5 and enolase 1 are also included in this group. Pancreatitis-associated protein is reported to be related to play a role in inflammatory pancreatitis (43) . Lysyl oxidase is an enzyme involved in extracellular matrix maturation (44) . Prostaglandin F2α is reported to have the ability to oxidize arachidonate. Galectin is a β-galactoside-binding protein that is related to the initiation of apoptosis. Enolase 1 is reported to be involved in the aging of neural cells (45) . The role of these proteins in the failing heart is unknown, and further investigations will be needed. Since Ca-handling proteins have not previously been reported to be involved in the mechanism of CCB on the heart, several Ca-handling protein genes, such as the voltage-dependent, T type, α1G subunit, S100 Ca-binding protein A4, cerebellar Ca-binding protein, and spot 35 protein genes, are also included in this group. Further study is needed to clarify the effect of these genes.
In contrary, in 195 genes, 85 genes were decreased in HS rats and increased in AMLO rats. In 85 genes, 38 genes were also increased in TEMP rats. These genes may be involved in the protective effects on heart failure. Some of these genes such as aquaporin 9, which is mostly changed, were not known as cardiovascular-related genes. Since macrophage migration inhibitory factor (MIF) is reported to delay the progression of apoptosis (46) , CD74, which is known as an MIFbinding protein (47) , may have important roles in the protective mechanism of amlodipine. Since the activation of coagulation is involved in the pathophysiology of heart failure, vitronectin, which is a co-factor along with plasminogen activator inhibitor 1 (48) for the inhibition of thrombin, is upregulated. Other changed genes may also have important roles in the beneficial mechanisms of amlodipine on the heart. A novel mechanism of amlodipine on the development of heart failure may become obvious by use of our result.
In conclusion, the present study demonstrated that the longterm CCB amlodipine has beneficial effects on a hypertensive heart failure model. A genome-wide study using a gene chip provided various clues that should be useful for determining the beneficial antioxidative mechanisms of amlodipine on hypertensive heart failure.
